Phase III miss wipes 60% off VBL Therapeutics share price

9 March 2018

Shares in Nasdaq-listed VBL Therapeutics (Nasdaq:VBLT) collapsed today after the Modiin, Israel-based oncology specialist revealed its Phase III GLOBE study missed its primary endpoint.

The top-line results from the study, which examined the candidate VB-111 in combination with Avastin (bevacizumab) in patients with recurrent glioblastoma (rGBM), show that the pre-specified endpoint of overall survival was not met.

With the firm’s stock trading 60% lower in New York, chief executive Dror Harats said he was “disappointed that our encouraging Phase II data were not replicated.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK